COMP <GO>
QGEN vs JNJ // EV/EBITDA & P/E VALUATION
Qiagen N.V. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: QGEN 6
— JNJ 8
▲ EV/EBITDA & P/E VALUATION LEADER: QGEN
LAST: $50.22 (-0.24%) • MKT CAP: $10.37B
valuation
17.6x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QGEN VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | QGEN | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.20% | 67.90% | -5.70 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.00% | 25.50% | -17.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 17.6x | 18.5x | -0.90 | QGEN | /valuation <GO> |
| Free Cash Flow Yield | 4.37% | 2.97% | +1.40 | QGEN | /fcf-yield <GO> |
| Operating Margin | 22.30% | 34.70% | -12.40 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 20.30% | 28.50% | -8.20 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 6.00% | -0.30 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.52% | 0.00% | +0.52 | QGEN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.54 | 5.59 | -2.05 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | QGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 72.4 | 62.1 | +10.30 | QGEN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.08 | -0.13 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.7x | 23.0x | -0.30 | QGEN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.37B | $662.49B | -$652.12B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | QGEN REV | JNJ REV | QGEN GROSS % | JNJ GROSS % | QGEN FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.09B | $94.19B | 62.2% | 67.9% | $453.3M | $19.70B |
| FY 2024 | $1.98B | $88.82B | 48.9% | 69.1% | $506.4M | $19.84B |
| FY 2023 | $1.97B | $85.16B | — | — | $371.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QGEN // BETA 0.95
JNJ // BETA 1.08